Pharmacology of kinins: Their relevance to tissue injury and inflammation

Marceau, François; Lussier, A; Regoli, Doménico; Giroud, Jean‐Paul

doi:10.1016/0306-3623(83)90001-0

Cited by 249 publications

(95 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, renal B, receptors were implicated in the action of BK on increased renal blood flow and sodium excretion in dogs (Lortie et al, 1992 (Barabe et al, 1979;Couture et al, 1981;Marceau et al, 1983;Drapeau et al, 1991b). This finding suggests that the functional B, receptor described in the present in vivo model under non-pathological conditions is somewhat different from the inducible B, receptor which has been described under pathological conditions.…”

Section: Discussionmentioning

confidence: 99%

“…Despite the very well known B2 receptor-mediated vasodepressor effect of kinins (Regoli & Barabe, 1980;Bhoola et al, 1992), the cardiovascular activity of the natural kininase I metabolite, des-Arg9-BK, which is a selective B, receptor agonist, has been less studied. This fact is due in part to the belief that B, receptors are not expressed in normal tissues but are synthesized de novo during tissue incubation in vitro and as a result of inflammation or exposure of tissue to chemical noxious stimuli in vivo (Marceau et al, 1983;Bouthillier et al, 1987). For instance, des-Arg9-BK had no significant effect on the cardiovascular system of rats and rabbits whereas exogenous des-Arg9-BK lowered mean arterial blood pressure through the activation of peripheral vascular B, receptors in rabbits pre-injected intravenously 5 h earlier with a bacterial lipopolysaccharide Marceau et al, 1983;Bouthillier et al, 1987).…”

Section: Introductionmentioning

confidence: 99%

“…This fact is due in part to the belief that B, receptors are not expressed in normal tissues but are synthesized de novo during tissue incubation in vitro and as a result of inflammation or exposure of tissue to chemical noxious stimuli in vivo (Marceau et al, 1983;Bouthillier et al, 1987). For instance, des-Arg9-BK had no significant effect on the cardiovascular system of rats and rabbits whereas exogenous des-Arg9-BK lowered mean arterial blood pressure through the activation of peripheral vascular B, receptors in rabbits pre-injected intravenously 5 h earlier with a bacterial lipopolysaccharide Marceau et al, 1983;Bouthillier et al, 1987). Nevertheless, under normal conditions, both B, and B2 receptors appear to mediate the vasodilator action of kinins in the canine renal artery in vitro (Rhaleb et al, 1989) as well as the vasorelaxation responsible for an increased renal blood flow in the dog in vivo (Lortie et al, 1992).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mediation by B₁ and B₂ receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs

Nakhostine

Ribuot

Lamontagne

et al. 1993

British J Pharmacology

View full text Add to dashboard Cite

1 Vasodepressor responses to intravenous (i.v.) injection of bradykinin (BK) and des-Arg9-BK, a selective B, kinin receptor agonist, were characterized following i.v. pretreatment with selective B, ([Leu8]-des-Arg9-BK) and B2 (Hoe 140) kinin receptor antagonists in anaesthetized dogs. 2 Des-Arg9-BK (0.05-3.3 nmol kg-') produced dose-dependent decreases in mean arterial blood pressure with a ED_0 0.4 nmol kg-'. The vasodepressor effects evoked by des-Arg9-BK (0.6 nmol kg-') and BK (0.2 nmol kg-') were greater after i.v. and i.a. injections, respectively. 3 The vasodepressor response to BK (0.6 nmol kg-') but not to des-Arg9-BK (0.6 nmol kg-') was significantly (P<0.001) blocked by pretreatment with the B2 receptor antagonist, Hoe 140. 4 The vasodepressor response to des-Arg9-BK (0.6 nmol kg-') but not to BK (0.6 nmol kg-') was significantly (P<0.001) reduced by pretreatment with the selective B, receptor antagonist, [Leu8]-desArg9-BK. Although both B, and B2 receptor antagonists caused a transient fall in blood pressure, their inhibitory action was unlikely to be related to a desensitization mechanism. 5 Inhibition of prostaglandin synthesis with indomethacin prevented the vasodepressor response induced by arachidonic acid (1 mg kg-', i.v.) but not that to BK or des-Arg9-BK (0.6 nmol kg-').6 These results suggest, firstly, that the vasodepressor responses to i.v. BK and des-Arg9-BK are mediated by the activation of B2 and B, receptors, respectively; secondly, that prostaglandins are not involved in the vasodepressor responses to kinins. These findings provide pharmacological evidence for the existence of functionally active B, receptors in canine cardiovascular homeostasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mediation by B₁ and B₂ receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs

Nakhostine

Ribuot

Lamontagne

et al. 1993

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Kinins are recognized as potent vasoactive peptides which promote venular dilatation, increased vascular permeability, enhanced fluid secretion from epithelia and produced pain and hyperalgesia (Lewis, 1970;Garcia Leme, 1978;Marceau et al, 1983;Proud & Kaplan, 1988;Steranka & Burch, 1991;Dray & Perkins, 1993). In addition, inflammation is associated with increased levels of BK and its metabolites des-Arg9-BK and des-Arg'0-Lys-BK (Regoli & Barabe, 1980;Hargreaves et al 1988;Damas et al, 1990).…”

Section: Introductionmentioning

confidence: 99%

“…This is likely to be because the B1 receptors are not expressed in normal tissues (Regoli & Barabe, 1980;Marceau et al, 1983;Steranka & Burch, 1991). Nevertheless, expression of B1 receptors can be induced under a variety of conditions, and thus exert important roles in several pathological states, including inflammation and hyperalgesia (Marceau et al, 1983;Farmer et al, 1991;Dray & Perkins, 1993;Perkins & Kelly, 1993). We have attempted to provide more direct evidence that B2 receptor desensitization induces the expression of B1 receptors, by pretreating animals with dexamethasone 24 h before intraplantar injection of DABK.…”

Section: Introductionmentioning

confidence: 99%

Involvement of B₁ and B₂ receptors in bradykinin‐induced rat paw oedema

Campos

Calixto

1995

British J Pharmacology

114

View full text Add to dashboard Cite

1 The mechanisms involved in bradykinin (BK)-induced oedema in the rat paw as well as the interactions between BK and several inflammatory mediators, have been investigated. 2 Intraplantar injection of BK (1 nmol/paw) in rats pretreated with captopril (5 mg kg-', s.c.) caused a small amount of oedema formation (0.17 ± 0.05 ml). Des-Arg9-BK (DABK, a selective B, receptor agonist) up to 300 nmol/paw caused minimal oedema (0.03 ± 0.01 ml). 3 Co-administration of prostaglandin E2 (PGE2), prostaglandin 12 (PGI2), calcitonin gene-related peptide (CGRP), 5-hydroxytryptamine (5-HT), substance P (SP) or platelet activating factor (PAF) (1 pmol-1 nmol/paw) with BK (1 nmol/paw) dose-dependently potentiated BK-induced paw oedema.The rank order of potency (mean EDm, pmol/paw) for this effect was: SP (8.1)>PAF (13.7)>PGI2 (DALBK, up to 300 nmol/paw) had no effect. 5 Daily intraplantar injections of BK (10 nmol/paw) once a day for 7 consecutive days caused a progressive and complete desensitization of the paw oedema, which was specific for BK, since paw oedema induced by PAF, PGE2, SP or histamine was not affected. In addition, the oedema caused by BK in the paw desensitized to the peptide was almost completely reversed if BK was co-injected with PGE2, PGI2 or SP (1 nmol/paw). Injection of PGE2 or SP (10 nmol/paw) together with the first BK injection (1O nmol/paw), partially prevented BK-induced desensitization. 6 When animals were completely desensitized to BK, DABK (100nmol/paw) caused paw oedema (0.25 ± 0.03 ml) which was consistently blocked by the B, receptor antagonist, DALBK (100 nmol/ paw).7 Treatment of animals with dexamethasone (0.5 mg kg-', s.c., 24 h previously) antagonized paw oedema induced by DABK (100 nmol/paw) in desensitized paws, but not that induced by BK (3 nmol/ paw) in naive paws. The steroid also prevented the recovery of oedema seen after co-injection of BK with PGE2 or PGI2 (1 nmol/paw) in desensitized paws. 8 These results suggest that both B, and B2 receptors are involved in BK-induced rat paw oedema. The B2 receptors are constitutive, but induction of expression of B, receptors seems to occur only after complete desensitization of the paw to BK. In addition, very low doses of inflammatory mediators markedly potentiate BK-induced paw oedema and can attenuate BK-induced paw oedema desensitization. Such mechanisms may be relevant for the manifestation of acute and chronic inflammatory processes.

show abstract

Distribution of bradykinin B2 receptors in sheep brain and spinal cord visualized by in vitro autoradiography

et al. 1997

View full text Add to dashboard Cite

Bradykinin B2 receptors were localized in the sheep brain and spinal cord by quantitative in vitro autoradiography using a radiolabelled and specific bradykinin B2 receptor antagonist analogue, 3-4-hydroxyphenyl-propionyl-D-Arg0-[Hyp3,Thi5,D-Tic 7,Oic8]bradykinin, (HPP-HOE 140). This radioligand displays high affinity and specificity for bradykinin B2 receptors. The respective K(i) values of 0.32, 1.37 and 156 nM were obtained for bradykinin, HOE140 and D-Arg[Hyp3,D-Phe7,Leu8]bradykinin competing for radioligand binding to lamina II of sheep spinal cord sections. Using this radioligand, we have demonstrated the distribution of bradykinin B2 receptors in many brain regions which have not been previously reported. The highest density of bradykinin B2 receptors occur in the pleoglial periaqueductal gray, oculomotor and trochlear nuclei and the circumventricular organs. Moderate densities of receptors occur in the substantia nigra, particularly the reticular part, the posterior thalamic and subthalamic nuclei, zona incerta, the red and pontine nuclei, some of the pretectal nuclei and in discrete layers of the superior colliculus. In the hindbrain, moderate levels of bradykinin B2 receptor binding occur in the nucleus of the solitary tract, and in spinal trigeminal, inferior olivary, cuneate and vestibular nuclei. Laminae II, X and dorsal root ganglia display the most striking binding densities in the spinal cord, while the remainder of the dorsal and ventral horn display a low and diffuse density of binding. Bradykinin B2 receptors are extensively distributed throughout the sheep brain and spinal cord, not only to sensory areas but also to areas involved in motor activity.

show abstract

Pharmacology of kinins: Their relevance to tissue injury and inflammation

Cited by 249 publications

References 81 publications

Mediation by B₁ and B₂ receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs

Mediation by B₁ and B₂ receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs

Involvement of B₁ and B₂ receptors in bradykinin‐induced rat paw oedema

Distribution of bradykinin B2 receptors in sheep brain and spinal cord visualized by in vitro autoradiography

Contact Info

Product

Resources

About

Pharmacology of kinins: Their relevance to tissue injury and inflammation

Cited by 249 publications

References 81 publications

Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs

Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs

Involvement of B1 and B2 receptors in bradykinin‐induced rat paw oedema

Distribution of bradykinin B2 receptors in sheep brain and spinal cord visualized by in vitro autoradiography

Contact Info

Product

Resources

About

Mediation by B₁ and B₂ receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs

Mediation by B₁ and B₂ receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs

Involvement of B₁ and B₂ receptors in bradykinin‐induced rat paw oedema